I. Discussion and analysis of operating conditions
2020 is an extremely special year, and the sudden COVID-19 epidemic has brought great challenges to the normal production and operation of the company. Facing the new situation, the company grasps the industry trend, focuses on the outstanding problems that restrict development, and actively takes countermeasures. On the one hand, orderly promote the resumption of work, stop production and limit production; On the other hand, efforts should be made to reduce costs and increase efficiency, adjust business strategies in time, find a turning point in the crisis, and fully achieve the company's annual budget target.
From June to June, 2020, the company realized an accumulated operating income of 62 1.2 billion yuan, which was basically the same as that of the same period last year. The net profit attributable to shareholders of listed companies was 327 million yuan, a year-on-year decrease of 65,438+02.29%.
During the reporting period, the Company mainly carried out the following work:
(A) to strengthen strategic guidance, clear implementation path
The company fully implements the construction of strategic system to enhance the scientificity, standardization and sustainability of the strategy. Establish a complete circular framework system consisting of strategic objectives, overall development planning, sub-planning, work plan, "JYKJ" system, planning evaluation and optimization, and clarify the implementation path. Initiate the preparation of the implementation plan of "strategy, planning and planning" system construction, covering industrial integration, M&A investment, international business development, emerging business development, comprehensive budget management system and internal control system, so as to guide the implementation of the Tenth Five-Year Plan.
(2) Continue to promote industrial integration and promote synergy.
Under the framework of medium-and long-term strategic planning, accelerate industry consolidation, further break through the industrial chain barriers from raw materials to preparations, accelerate the integration of production capacity and resources, and form an integrated supporting scheme for raw materials and preparations through enterprise linkage, realizing the optimal connection of nearly 30 varieties and improving the quality and efficiency of coordination; In terms of marketing integration, CRM data system is used to speed up marketing integration, comprehensively supervise and improve the compliance management system, accelerate the construction of a marketing system that adapts to the new situation, and strive to improve the management and control capabilities of sales channels, policy affairs, brands and terminals.
(c) Promoting technological innovation and endogenous development.
The company continued to implement the "innovation-driven" development strategy, and increased R&D investment during the reporting period, with a year-on-year increase of 65,438+04.69%. Focus on project management, implement key supervision and whole process control mode, and fully promote consistency evaluation. During the reporting period, four varieties of diclofenac sodium sustained-release tablets, cefdinir dispersible tablets, cefixime granules and clarithromycin tablets passed the consistency evaluation, and three items were declared for consistency evaluation. Up to the disclosure date of this report, eight varieties (10 product specifications) of the company have passed the conformity evaluation, and dexmedetomidine hydrochloride injection is deemed to have passed the conformity evaluation. During the reporting period, the company applied for new patents 14 (including 7 invention patents and 7 utility model patents) and obtained 8 newly authorized invention patents.
(4) Improve management level and strengthen risk control.
The company continued to implement the large variety strategy, adopted the implementation plan of "one product, one policy", strengthened academic and brand promotion, explored online cooperation, and constantly optimized the layout of large varieties; Carry out lean management in depth, strengthen the work of reducing costs and increasing efficiency, pay attention to cost control, pay attention to on-site management, improve OEE and optimize processes. And form a lean production management system; Continue to improve quality and efficiency, implement financial control, effectively reduce the cost of capital, and the sales of management fee rate decreased by 3.88 percentage points year-on-year; In improving the internal control system, optimizing the organizational structure, strengthening business execution, sorting out major risks and completing the rolling assessment of risk pools; Take legal affairs as the guide, special audit as the starting point, cooperate with party Committee inspection, and accelerate the formation of the company's internal control inspection network; Fully implement the main responsibilities of enterprise safety, environmental protection and quality, and establish a special supervision mechanism to improve the effectiveness of risk control.
(5) Highlight the Party's leadership and ensure the construction of "three basics".
The company insists on taking the party's political construction as the guide, deepens the achievements of theme education, and aims at shortcomings and strong and weak items, and conducts in-depth research to solve outstanding problems; Strengthen grassroots party building, strictly implement the "three majors and one big" decision-making procedure, conscientiously implement the "three basics construction", strengthen party member's belief, and optimize the internal environment of enterprises; Fully implement the requirements of strictly administering the party in an all-round way, improve the level of party building and management, and provide a strong political guarantee for comprehensively improving the company's development capabilities.
Second, possible risks
In the face of environmental factors such as the current slowdown in pharmaceutical economic growth, frequent industrial policies, and stricter safety and environmental protection supervision, the company's future development may face the following main risks:
1, industry policy risk
The development of pharmaceutical industry in China is greatly influenced by policy supervision. In 20 19, industrial policies such as medical insurance catalogue adjustment, medical accounting information quality inspection and DRGs pilot were introduced one after another, which had a great impact and influence on drug research and development, production and sales. In 2020, the state will continue to promote the implementation of regulatory policies, and the industry concentration will be significantly improved in the future. The adjustment of industrial policy will bring challenges to the business development of enterprises.
2. The risk of drug price reduction
From 2065438 to 2009, the national centralized drug procurement pilot was further promoted and implemented, and the sales price of generic drugs was greatly reduced. With the deepening of medical reform, under the policy guidance of implementing drug price reduction measures and controlling medical expenses, drug prices may continue to decline in the future, which will challenge the profitability of some products of the company.
3. Risk of technology research and development
With the continuous promotion of national centralized drug procurement and variety expansion, pharmaceutical manufacturers will be forced to speed up consistency evaluation.
If the drug consistency evaluation of drug manufacturers fails to meet expectations, enterprises will lose market competition opportunities and face the risk of market share erosion.
Countermeasures: The company will strengthen the management of scientific research projects, increase the support of consistency evaluation, give inclined support in organizational guarantee, R&D team support, fund matching and foreign cooperation, and comprehensively promote consistency evaluation.
4. Environmental risks
The 19th National Congress of the Communist Party of China will resolutely fight the battle against pollution as one of the three major battles to build a well-off society in an all-round way. The pharmaceutical production process involves a variety of complex chemical reactions, which inevitably produces wastewater, waste gas and solid waste ("three wastes") that need to be treated. With the promotion of national and local environmental supervision and the improvement of pollution discharge standards, the environmental risks brought by the treatment of three wastes have intensified. Enterprises are faced with risks such as changes in environmental protection policies, increased difficulties in governance, equipment and process updates, and increased environmental protection expenditures.
Countermeasures: the company takes "environmental protection is the core competitiveness of enterprises" as the guiding ideology, and constantly strengthens environmental protection laws and regulations and professional knowledge training; Continue to strengthen the judgment and foresight of environmental protection policies; We will continue to increase investment in new technologies and equipment for environmental protection, improve the effectiveness and management level of environmental protection work, build a whole-process, multi-level risk prevention system, improve risk prevention and control capabilities, and resolve risks from the source.
5, quality control risk
The company has a wide range of products, complex production process and long production process, and the production of drugs requires high equipment, environment and technology. 20 19 12 1 The promulgation and implementation of the newly revised Drug Administration Law marks the arrival of the "four strictest" times facing the pharmaceutical industry-the strictest standards, the strictest supervision, the severest punishment and the most serious accountability. If the company's quality control ability can't adapt to the continuous growth of business scale, it may have an adverse impact on the company's brand image and operation.
Countermeasures: the company will firmly establish the quality consciousness of all staff, attach importance to the training and learning of quality management, and make unremitting efforts; Clear quality control standards, strengthen quality tracking and flight inspection, continue to carry out technological innovation and process optimization, continue to carry out special activities to improve quality, and carry out production and business activities in compliance; Improve the company's quality control ability from the mechanism, continuously improve the emergency handling ability of quality emergencies, do a good job in product information traceability, and strengthen product quality control.
Three. Analysis of core competitiveness during the reporting period
The company is a unified platform for the development of chemical pharmaceutical industry under Sinopharm Group, and its products focus on anti-infection, anti-tumor, cardiovascular and cerebrovascular diseases, anesthesia psychology, metabolism and endocrine. The products are distributed in the treatment field with the largest scale and the greatest growth potential in China pharmaceutical market, and have formed the whole industrial chain coverage of pharmaceutical industries such as raw materials and intermediates, chemical preparations and biological products, and have certain comprehensive strength and market competitiveness in the market segments such as antibiotics, cardiovascular and cerebrovascular diseases and anesthetics. During the reporting period, the company's core competitiveness has not changed significantly.
1, industrial platform advantages
The company belongs to Sinopharm Group, the largest "medical and health industrial platform for central enterprises" in China, and is positioned as a chemical and pharmaceutical platform under Sinopharm Group, which has the advantage of industrial platform. At present, the company has formed a professional development pattern with unified strategy, centralized resources, reasonable allocation, scale effect and synergistic advantages of upstream and downstream industrial chains. According to the planning and deployment, the company will continue to deepen the advantages of the chemical, pharmaceutical and health industry platform and achieve leap-forward development through all-round cooperation in the industry.
2. Internal synergy advantages
As a chemical and pharmaceutical industry platform under Sinopharm Group, based on five major product areas, it builds a business segment development platform, comprehensively links and coordinates resource management within the segment, and promotes internal integration, resource sharing and balanced development of enterprises. The R&D line has gradually formed a multi-level R&D system with the parent company as the overall center and technical core, realizing the complementary advantages of R&D resources; In terms of industrial chain, a complete industrial chain integrating concentrated intermediates, raw materials and preparation products has been formed, and the upstream and downstream of the industrial chain can effectively reduce costs and increase profits; In terms of procurement, under the framework of centralized procurement, the company's bargaining power is further improved, thus reducing procurement costs; In terms of marketing integration, products in the same therapeutic field can use marketing resources, and the expansion of marketing channels and coverage will help to enhance market share and brand awareness.
3. External synergy advantages
The company actively participated in the strategic planning of "family relationship" of Sinopharm Group and continued to strengthen cooperation with Sinopharm Holdings, the internal commercial giant of Sinopharm Group. As a shareholder of the company, Sinopharm Holdings has the power to vigorously promote the company's business development. At the same time, the comprehensive promotion of the "two-vote system" in the whole country has further consolidated its dominant position as the largest distributor and retailer in China. Taking this as an opportunity, the company has continuously deepened its strategic cooperation with distributors including Sinopharm Holdings, realized industrial and commercial strategic coordination, and given full play to its external synergy advantages.
4.R&D advantages
With "innovation-driven" as the driving force for sustainable development, the company has established a multi-level R&D system with the parent company as the overall center, forming a comprehensive enterprise technology innovation system with clear organization, leading advantages, professional division of labor, resource concentration and Industry-University-Research. During the reporting period, the company obtained 8 newly authorized invention patents; As of the disclosure date of this report, the company has passed the conformity evaluation for 8 varieties (10 product specifications), and 1 drugs are deemed to have passed the conformity evaluation.
5. Brand advantage
Companies adhere to the implementation of brand strategy, constantly consolidate and enhance brand influence, and establish a high public awareness. It owns a series of well-known brands such as Xin Ran, Dalifen, Dalixin, Wichita, Shenjia, Shenluo, Pledge, Puhuizhi, Jinshi Graphic Trademark, Lifefan and so on.
Our products have also established a certain brand awareness in the international market. The production places of zidovudine and azithromycin from modern Haimen, the series products of cephalosporin intermediates 7ACA, D-7ACA and 7ACT from Sinopharm, and the intermediates 6APA from penicillin, amoxicillin and Tianwei Bio all passed the US FDA certification. Tianwei Bio's clavulanic acid series products, amoxicillin, lipoic acid and micafenone sodium have passed the European CEP certification. Some products of this foreign medicine Wichita have passed the official certification in India, South Korea and other places; Tianwei biological raw material medicine has passed the official examination and certification in Japan; Sinopharm Zhizhi has obtained EU certification and WHO certification for cephalosporin powder injection and oral preparation.